Levofloxacin

Generic Name: Levofloxacin

Brand Names: Levaquin, Quinsair

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₀FN_₃O_₄

CAS Number: 100986-85-4

Unique Ingredient Identifier: RIX4E89Y14

Background: Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic ofloxacin. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along w...

Indication: In oral and intravenous formulations, levofloxacin is indicated in adults for the treatment of various infections caused by susceptible bacteria, including infections of the upper respiratory tract, lower respiratory tract, skin, skin structures, urinary tract, and prostate. The oral formulation is also indicated in both adults and children 6 months of age a...

Associated Conditions: Abscesses caused by susceptible bacteria, Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) caused by susceptible bacteria, Acute Pyelonephritis caused by Infection Due to Escherichia Coli, Bacterial Conjunctivitis caused by susceptible bacteria, Cellulitis caused by susceptible bacteria, Community Acquired Pneumonia (CAP) caused by susceptible bacteria, Furuncle caused by susceptible bacteria, Impetigo caused by susceptible bacteria, Inhalational Anthrax, Nosocomial Pneumonia caused by Pseudomonas Infections, Nosocomial Pneumonia caused by susceptible bacteria, Plague caused by Yersinia pestis, Pyoderma caused by susceptible bacteria, Wound Infections caused by susceptible bacteria, Acute bacterial sinusitis caused by susceptible bacteria, Chronic Bacterial prostatitis caused by susceptible bacteria, Chronic Pseudomonas Infections, Complicated Urinary Tract Infection caused by susceptible bacteria, Complicated skin and skin-structure infections caused by susceptible bacteria, Uncomplicated Urinary Tract Infection caused by susceptible bacteria, Uncomplicated skin and skin-structure infections caused by susceptible bacteria

Associated Therapies: -

Clinical Trials

Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach

Phase 2

Terminated

Conditions: Non-Hodgkin's Lymphoma
Cancer

Interventions: Drug: Vincristine
Drug: VP-16
Drug: Rituximab
Drug: Dexamethasone
Drug: Levofloxacin

First Posted Date: 2005-11-08

Last Posted Date: 2015-08-03

Lead Sponsor: New Mexico Cancer Care Alliance

Target Recruit Count: 17

Registration Number: NCT00250718

Locations: 🇺🇸
University of New Mexico Cancer Center, Albuquerque, New Mexico, United States

A Study of the Safety and Effectiveness of Levofloxacin Compared With Amoxicillin/Clavulanate Potassium in the Treatment of Adults With Rapid Onset of Severe Inflammation/Infection of the Sinuses

Phase 3

Completed

Conditions: Sinusitis
Maxillary Sinusitis

First Posted Date: 2005-11-07

Last Posted Date: 2011-06-10

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 614

Registration Number: NCT00249210

A Study of the Safety and Effectiveness of Levofloxacin Compared to Ticarcillin/Clavulanate Alone or Followed by Amoxicillin/Clavulanate in the Treatment of Complicated Skin Infections

Phase 3

Completed

Conditions: Skin Diseases, Bacterial

First Posted Date: 2005-11-07

Last Posted Date: 2011-06-10

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 413

Registration Number: NCT00249197

Urinary Tract Infection Study With the Antibiotic Levofloxacin Given at a Higher Dose Over a Shorter Period of Time

Phase 4

Terminated

Conditions: Complicated Urinary Infection

First Posted Date: 2005-10-28

Last Posted Date: 2015-06-03

Lead Sponsor: University of Manitoba

Target Recruit Count: 30

Registration Number: NCT00245791

Locations: 🇨🇦
University of Manitoba, Winnipeg, Manitoba, Canada
🇨🇦
Health Sciences Centre, Winnipeg, Manitoba, Canada
🇨🇦
St. Boniface General Hospital, Winnipeg, Manitoba, Canada

Safety and Efficacy Study of the Treatment of Kidney Infections With Short Course Levofloxacin

Phase 4

Terminated

Conditions: Acute Uncomplicated Pyelonephritis

First Posted Date: 2005-10-14

Last Posted Date: 2005-10-14

Lead Sponsor: University of Manitoba

Target Recruit Count: 30

Registration Number: NCT00239161

Locations: 🇨🇦
Misericordia Urgent Care, Winnipeg, Manitoba, Canada
🇨🇦
St. Boniface General Hospital, Winnipeg, Manitoba, Canada
🇨🇦
University of Manitoba, Winnipeg, Manitoba, Canada

and more 1 locations